Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Publication/Presentation Date
5-1-2011
Abstract
How do oncologists choose therapy for the elderly? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC = 2) + paclitaxel 50 mg/m(2) days 1, 8, 15 (28-day cycle × 4) followed by gefitinib; or (b) gefitinib 250 mg/day. With (a), 12 of 34 were progression-free at 6 months; median time to cancer progression was 3.9 months. With (b), the same occurred in 11 of 28 patients with the latter being 4.9 months. The most common reason for conventional chemotherapy was oncologists' opinion that the cancer was aggressive, and for gefitinib alone, patients' reluctance to receive chemotherapy. Interestingly, age had no influence.
Volume
29
Issue
4
First Page
266
Last Page
271
ISSN
1532-4192
Published In/Presented At
Mc Kean, H., Stella, P. J., Hillman, S. L., Rowland, K. M., Cannon, M. W., Behrens, R. J., Gross, G. G., Sborov, M. D., Friedman, E. L., & Jatoi, A. (2011). Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222. Cancer investigation, 29(4), 266–271. https://doi.org/10.3109/07357907.2010.535061
Disciplines
Medicine and Health Sciences
PubMedID
21345074
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article